Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled

Repackaged versions of many of the most widely prescribed brand-name drugs appear on a list of those with "extraordinary" price increases between 2000 and 2008, data from a recent analysis by the Government Accountability Office show

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011